Impact of Expression of Vimentin and Axl in Breast Cancer

Kimihiro Tanaka, Eriko Tokunaga, Yuka Inoue, Nami Yamashita, Hiroshi Saeki, Shinji Okano, Hiroyuki Kitao, Eiji Oki, Yoshinao Oda, Yoshihiko Maehara

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The receptor tyrosine kinase Axl has been reported to be a downstream effector of epithelial-to-mesenchymal transition and to be regulated by vimentin expression in preclinical models. Coexistence of vimentin-positive and Axl-high expression was significantly associated with triple-negative breast cancer and poor prognosis. Vimentin and Axl expression might contribute to the aggressive phenotype in breast cancer patients. Background The association between Axl and vimentin protein expression has been observed in several cell lines. However, the clinical importance of Axl and vimentin expression in breast cancer have not been fully determined. Patients and Methods The expressions of Axl and vimentin were evaluated by immunohistochemistry in a total of 343 patients with invasive ductal carcinoma. The relationships between expression of Axl and vimentin and clinicopathologic characteristics and prognosis were analyzed. Results Axl expression was classified into high (n = 170) and low (n = 173) expression groups. Axl expression alone was not associated with any clinicopathologic factor or prognosis. Coexistence of vimentin-positive and Axl-high expression was observed in 10.5% (n = 36). Vimentin-positive and Axl-high tumors were associated with triple-negative breast cancers (P = .0396) and with poor prognosis in terms of both recurrence-free survival (P = .0126) and overall survival (P = .0005) compared to the other groups, including vimentin-positive and Axl-low tumors, vimentin-negative and Axl-high tumors, and vimentin-negative and Axl-low tumors. Multivariate analysis showed that coexistence of vimentin-positive and Axl-high expression was an independent poor prognostic factor for recurrence-free survival (hazard ratio, 2.78; 95% confidence interval, 1.23-5.68; P = .0158) and overall survival (hazard ratio, 3.72; 95% confidence interval, 1.51-8.47; P = .0059). Conclusion Coexistence of vimentin-positive and Axl-high expression is a poor prognostic factor for primary breast cancer. Vimentin and Axl expression might contribute to the aggressive phenotype in breast cancer.

Original languageEnglish
Pages (from-to)520-526.e2
JournalClinical Breast Cancer
Volume16
Issue number6
DOIs
Publication statusPublished - Dec 1 2016

Fingerprint

Vimentin
Breast Neoplasms
Triple Negative Breast Neoplasms
Survival
Neoplasms
Confidence Intervals
Phenotype
Recurrence
Ductal Carcinoma
Epithelial-Mesenchymal Transition

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Tanaka, K., Tokunaga, E., Inoue, Y., Yamashita, N., Saeki, H., Okano, S., ... Maehara, Y. (2016). Impact of Expression of Vimentin and Axl in Breast Cancer. Clinical Breast Cancer, 16(6), 520-526.e2. https://doi.org/10.1016/j.clbc.2016.06.015

Impact of Expression of Vimentin and Axl in Breast Cancer. / Tanaka, Kimihiro; Tokunaga, Eriko; Inoue, Yuka; Yamashita, Nami; Saeki, Hiroshi; Okano, Shinji; Kitao, Hiroyuki; Oki, Eiji; Oda, Yoshinao; Maehara, Yoshihiko.

In: Clinical Breast Cancer, Vol. 16, No. 6, 01.12.2016, p. 520-526.e2.

Research output: Contribution to journalArticle

Tanaka, K, Tokunaga, E, Inoue, Y, Yamashita, N, Saeki, H, Okano, S, Kitao, H, Oki, E, Oda, Y & Maehara, Y 2016, 'Impact of Expression of Vimentin and Axl in Breast Cancer', Clinical Breast Cancer, vol. 16, no. 6, pp. 520-526.e2. https://doi.org/10.1016/j.clbc.2016.06.015
Tanaka, Kimihiro ; Tokunaga, Eriko ; Inoue, Yuka ; Yamashita, Nami ; Saeki, Hiroshi ; Okano, Shinji ; Kitao, Hiroyuki ; Oki, Eiji ; Oda, Yoshinao ; Maehara, Yoshihiko. / Impact of Expression of Vimentin and Axl in Breast Cancer. In: Clinical Breast Cancer. 2016 ; Vol. 16, No. 6. pp. 520-526.e2.
@article{9b95bff5978e4ad48c3abc7c6420f774,
title = "Impact of Expression of Vimentin and Axl in Breast Cancer",
abstract = "The receptor tyrosine kinase Axl has been reported to be a downstream effector of epithelial-to-mesenchymal transition and to be regulated by vimentin expression in preclinical models. Coexistence of vimentin-positive and Axl-high expression was significantly associated with triple-negative breast cancer and poor prognosis. Vimentin and Axl expression might contribute to the aggressive phenotype in breast cancer patients. Background The association between Axl and vimentin protein expression has been observed in several cell lines. However, the clinical importance of Axl and vimentin expression in breast cancer have not been fully determined. Patients and Methods The expressions of Axl and vimentin were evaluated by immunohistochemistry in a total of 343 patients with invasive ductal carcinoma. The relationships between expression of Axl and vimentin and clinicopathologic characteristics and prognosis were analyzed. Results Axl expression was classified into high (n = 170) and low (n = 173) expression groups. Axl expression alone was not associated with any clinicopathologic factor or prognosis. Coexistence of vimentin-positive and Axl-high expression was observed in 10.5{\%} (n = 36). Vimentin-positive and Axl-high tumors were associated with triple-negative breast cancers (P = .0396) and with poor prognosis in terms of both recurrence-free survival (P = .0126) and overall survival (P = .0005) compared to the other groups, including vimentin-positive and Axl-low tumors, vimentin-negative and Axl-high tumors, and vimentin-negative and Axl-low tumors. Multivariate analysis showed that coexistence of vimentin-positive and Axl-high expression was an independent poor prognostic factor for recurrence-free survival (hazard ratio, 2.78; 95{\%} confidence interval, 1.23-5.68; P = .0158) and overall survival (hazard ratio, 3.72; 95{\%} confidence interval, 1.51-8.47; P = .0059). Conclusion Coexistence of vimentin-positive and Axl-high expression is a poor prognostic factor for primary breast cancer. Vimentin and Axl expression might contribute to the aggressive phenotype in breast cancer.",
author = "Kimihiro Tanaka and Eriko Tokunaga and Yuka Inoue and Nami Yamashita and Hiroshi Saeki and Shinji Okano and Hiroyuki Kitao and Eiji Oki and Yoshinao Oda and Yoshihiko Maehara",
year = "2016",
month = "12",
day = "1",
doi = "10.1016/j.clbc.2016.06.015",
language = "English",
volume = "16",
pages = "520--526.e2",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "6",

}

TY - JOUR

T1 - Impact of Expression of Vimentin and Axl in Breast Cancer

AU - Tanaka, Kimihiro

AU - Tokunaga, Eriko

AU - Inoue, Yuka

AU - Yamashita, Nami

AU - Saeki, Hiroshi

AU - Okano, Shinji

AU - Kitao, Hiroyuki

AU - Oki, Eiji

AU - Oda, Yoshinao

AU - Maehara, Yoshihiko

PY - 2016/12/1

Y1 - 2016/12/1

N2 - The receptor tyrosine kinase Axl has been reported to be a downstream effector of epithelial-to-mesenchymal transition and to be regulated by vimentin expression in preclinical models. Coexistence of vimentin-positive and Axl-high expression was significantly associated with triple-negative breast cancer and poor prognosis. Vimentin and Axl expression might contribute to the aggressive phenotype in breast cancer patients. Background The association between Axl and vimentin protein expression has been observed in several cell lines. However, the clinical importance of Axl and vimentin expression in breast cancer have not been fully determined. Patients and Methods The expressions of Axl and vimentin were evaluated by immunohistochemistry in a total of 343 patients with invasive ductal carcinoma. The relationships between expression of Axl and vimentin and clinicopathologic characteristics and prognosis were analyzed. Results Axl expression was classified into high (n = 170) and low (n = 173) expression groups. Axl expression alone was not associated with any clinicopathologic factor or prognosis. Coexistence of vimentin-positive and Axl-high expression was observed in 10.5% (n = 36). Vimentin-positive and Axl-high tumors were associated with triple-negative breast cancers (P = .0396) and with poor prognosis in terms of both recurrence-free survival (P = .0126) and overall survival (P = .0005) compared to the other groups, including vimentin-positive and Axl-low tumors, vimentin-negative and Axl-high tumors, and vimentin-negative and Axl-low tumors. Multivariate analysis showed that coexistence of vimentin-positive and Axl-high expression was an independent poor prognostic factor for recurrence-free survival (hazard ratio, 2.78; 95% confidence interval, 1.23-5.68; P = .0158) and overall survival (hazard ratio, 3.72; 95% confidence interval, 1.51-8.47; P = .0059). Conclusion Coexistence of vimentin-positive and Axl-high expression is a poor prognostic factor for primary breast cancer. Vimentin and Axl expression might contribute to the aggressive phenotype in breast cancer.

AB - The receptor tyrosine kinase Axl has been reported to be a downstream effector of epithelial-to-mesenchymal transition and to be regulated by vimentin expression in preclinical models. Coexistence of vimentin-positive and Axl-high expression was significantly associated with triple-negative breast cancer and poor prognosis. Vimentin and Axl expression might contribute to the aggressive phenotype in breast cancer patients. Background The association between Axl and vimentin protein expression has been observed in several cell lines. However, the clinical importance of Axl and vimentin expression in breast cancer have not been fully determined. Patients and Methods The expressions of Axl and vimentin were evaluated by immunohistochemistry in a total of 343 patients with invasive ductal carcinoma. The relationships between expression of Axl and vimentin and clinicopathologic characteristics and prognosis were analyzed. Results Axl expression was classified into high (n = 170) and low (n = 173) expression groups. Axl expression alone was not associated with any clinicopathologic factor or prognosis. Coexistence of vimentin-positive and Axl-high expression was observed in 10.5% (n = 36). Vimentin-positive and Axl-high tumors were associated with triple-negative breast cancers (P = .0396) and with poor prognosis in terms of both recurrence-free survival (P = .0126) and overall survival (P = .0005) compared to the other groups, including vimentin-positive and Axl-low tumors, vimentin-negative and Axl-high tumors, and vimentin-negative and Axl-low tumors. Multivariate analysis showed that coexistence of vimentin-positive and Axl-high expression was an independent poor prognostic factor for recurrence-free survival (hazard ratio, 2.78; 95% confidence interval, 1.23-5.68; P = .0158) and overall survival (hazard ratio, 3.72; 95% confidence interval, 1.51-8.47; P = .0059). Conclusion Coexistence of vimentin-positive and Axl-high expression is a poor prognostic factor for primary breast cancer. Vimentin and Axl expression might contribute to the aggressive phenotype in breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=84995688273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995688273&partnerID=8YFLogxK

U2 - 10.1016/j.clbc.2016.06.015

DO - 10.1016/j.clbc.2016.06.015

M3 - Article

VL - 16

SP - 520-526.e2

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 6

ER -